Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2010

01-05-2010 | Epidemiology

IGF-I during primiparous pregnancy and maternal risk of breast cancer

Authors: Tianhui Chen, Annekatrin Lukanova, Kjell Grankvist, Anne Zeleniuch-Jacquotte, Marianne Wulff, Robert Johansson, Helena Schock, Per Lenner, Goran Hallmans, Goran Wadell, Paolo Toniolo, Eva Lundin

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

Previously, we reported that insulin-like growth factor (IGF)-I during early pregnancy is positively associated with maternal risk of breast cancer. To further explore this association, we designed a new study limited to women who donated a blood sample during their first pregnancy ending with childbirth. A case–control study was nested within the Northern Sweden Maternity Cohort in which repository since 1975, serum specimens remaining after early pregnancy screening for infectious diseases had been preserved. Study subjects were selected among women who donated a blood sample during the full-term pregnancy that led to the birth of their first child. Two hundred and forty-four women with invasive breast cancer were eligible. Two controls, matching the index case for age and date at blood donation were selected (n = 453). IGF-I was measured in serum samples on an Immulite 2000 analyzer. Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals. A significant positive association of breast cancer with IGF-I was observed, with OR of 1.73 (95% CI: 1.14–2.63) for the top tertile, P < 0.009. Subgroup analyses did not indicate statistical heterogeneity of the association by ages at sampling and diagnosis or by lag time to cancer diagnosis, although somewhat stronger associations with risk were observed in women ≤age 25 at index pregnancy and for cases diagnosed within 15 years of blood donation. The results of the study add further evidence for an adverse effect of elevated IGF-I concentrations during early reproductive life on risk of breast cancer.
Literature
1.
go back to reference Lukanova A, Toniolo P, Zeleniuch-Jacquotte A et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:2489–2493CrossRefPubMed Lukanova A, Toniolo P, Zeleniuch-Jacquotte A et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:2489–2493CrossRefPubMed
2.
go back to reference Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353CrossRefPubMed Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353CrossRefPubMed
3.
go back to reference Fletcher O, Gibson L, Johnson N et al (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19PubMed Fletcher O, Gibson L, Johnson N et al (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19PubMed
4.
go back to reference Lukanova A, Andersson R, Wulff M et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case–control study. Am J Epidemiol 168:1284–1291CrossRefPubMed Lukanova A, Andersson R, Wulff M et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case–control study. Am J Epidemiol 168:1284–1291CrossRefPubMed
5.
go back to reference Cnattingius S, Ericson A, Gunnarskog J, Kallen B (1990) A quality study of a medical birth registry. Scand J Soc Med 18:143–148PubMed Cnattingius S, Ericson A, Gunnarskog J, Kallen B (1990) A quality study of a medical birth registry. Scand J Soc Med 18:143–148PubMed
6.
go back to reference Monaghan JM, Godber IM, Lawson N et al (2004) Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 41:220–226CrossRefPubMed Monaghan JM, Godber IM, Lawson N et al (2004) Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 41:220–226CrossRefPubMed
7.
go back to reference Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577PubMed Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577PubMed
8.
go back to reference Richardson BE, Hulka BS, Peck JL et al (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727PubMed Richardson BE, Hulka BS, Peck JL et al (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727PubMed
9.
go back to reference Cleveland WS, Loader C (1996) Smoothing by local regression: principles and methods. In: Schimek MG (ed) Statistical theory and computational aspects of smoothing, 1st edn. Springer, New York, pp 113–120 Cleveland WS, Loader C (1996) Smoothing by local regression: principles and methods. In: Schimek MG (ed) Statistical theory and computational aspects of smoothing, 1st edn. Springer, New York, pp 113–120
10.
go back to reference Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665–1677CrossRefPubMed Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665–1677CrossRefPubMed
11.
go back to reference Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47:209–217CrossRefPubMed Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47:209–217CrossRefPubMed
12.
go back to reference Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6 Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6
13.
go back to reference Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86:723–727CrossRefPubMed Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86:723–727CrossRefPubMed
14.
go back to reference Jones RA, Moorehead RA (2008) The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 13:407–413CrossRefPubMed Jones RA, Moorehead RA (2008) The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 13:407–413CrossRefPubMed
15.
go back to reference Rowzee AM, Lazzarino DA, Rota L, Sun Z, Wood TL (2008) IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia 13:361–370CrossRefPubMed Rowzee AM, Lazzarino DA, Rota L, Sun Z, Wood TL (2008) IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia 13:361–370CrossRefPubMed
16.
go back to reference Kleinberg DL, Wood TL, Furth PA, Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51–74CrossRefPubMed Kleinberg DL, Wood TL, Furth PA, Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51–74CrossRefPubMed
17.
go back to reference Loladze AV, Stull MA, Rowzee AM et al (2006) Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology 147:5412–5423CrossRefPubMed Loladze AV, Stull MA, Rowzee AM et al (2006) Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology 147:5412–5423CrossRefPubMed
18.
go back to reference Bonnette SG, Hadsell DL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945CrossRefPubMed Bonnette SG, Hadsell DL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945CrossRefPubMed
19.
go back to reference Hall K, Enberg G, Hellem E et al (1984) Somatomedin levels in pregnancy: longitudinal study in healthy subjects and patients with growth hormone deficiency. J Clin Endocrinol Metab 59:587–594CrossRefPubMed Hall K, Enberg G, Hellem E et al (1984) Somatomedin levels in pregnancy: longitudinal study in healthy subjects and patients with growth hormone deficiency. J Clin Endocrinol Metab 59:587–594CrossRefPubMed
20.
go back to reference Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone—a review. Placenta 23(Suppl A):S87–S94CrossRefPubMed Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone—a review. Placenta 23(Suppl A):S87–S94CrossRefPubMed
21.
go back to reference Eriksson L, Frankenne F, Eden S, Hennen G, von Schoultz B (1989) Growth hormone 24-h serum profiles during pregnancy—lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 96:949–953PubMed Eriksson L, Frankenne F, Eden S, Hennen G, von Schoultz B (1989) Growth hormone 24-h serum profiles during pregnancy—lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 96:949–953PubMed
22.
go back to reference Hancock SL, Tucker MA, Hoppe RT (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31CrossRefPubMed Hancock SL, Tucker MA, Hoppe RT (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31CrossRefPubMed
23.
go back to reference Ronckers CM, Erdmann CA, Land CE (2005) Radiation and breast cancer: a review of current evidence. Breast Cancer Res 7:21–32CrossRefPubMed Ronckers CM, Erdmann CA, Land CE (2005) Radiation and breast cancer: a review of current evidence. Breast Cancer Res 7:21–32CrossRefPubMed
24.
go back to reference Grubbs CJ, Peckham JC, Cato KD (1983) Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administration. J Natl Cancer Inst 70:209–212PubMed Grubbs CJ, Peckham JC, Cato KD (1983) Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administration. J Natl Cancer Inst 70:209–212PubMed
25.
go back to reference Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49–61CrossRefPubMed Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49–61CrossRefPubMed
26.
go back to reference Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Cause Control 13:299–305CrossRef Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Cause Control 13:299–305CrossRef
27.
go back to reference Pathak DR (2002) Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Cause Control 13:295–298CrossRef Pathak DR (2002) Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Cause Control 13:295–298CrossRef
28.
go back to reference Wood TL, Richert MM, Stull MA, Allar MA (2000) The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 5:31–42CrossRefPubMed Wood TL, Richert MM, Stull MA, Allar MA (2000) The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 5:31–42CrossRefPubMed
29.
go back to reference Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, Leroith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97:2225–2232CrossRefPubMed Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, Leroith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97:2225–2232CrossRefPubMed
30.
Metadata
Title
IGF-I during primiparous pregnancy and maternal risk of breast cancer
Authors
Tianhui Chen
Annekatrin Lukanova
Kjell Grankvist
Anne Zeleniuch-Jacquotte
Marianne Wulff
Robert Johansson
Helena Schock
Per Lenner
Goran Hallmans
Goran Wadell
Paolo Toniolo
Eva Lundin
Publication date
01-05-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0519-6

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine